美國藥品市場展望：2011∼2021年 是由出版商Visiongain在2010年12月所出版的。
這份英文市場調查報告書包含170 Pages 價格從美金2331起跳。
本報告書為美國藥品市場的相關分析，包含市場全體概要與處方藥、OTC藥品、副廠藥品的各領域市場動向、主要企業的簡介等、專家見解與SWOT分析結果，概述如下。
第1章 總綱
第2章 2010年美國藥品市場
第3章 美國市場概要：2011∼2021年
- 美國市場收益大幅增加
- 中樞神經系統產品預測
- 癌產品
- 抗感染藥
- 消化／代謝產品
- 其他
第4章 美國市場的主要產品
- Lipitor
- Plavix
- Seretide
- Seroquel
- Ramicade
第5章 美國市場的主要企業
- Pfizer
- Roche
- AstraZeneca
- Merck & Co.
- Novartis
第6章 美國的副廠藥品市場：2011∼2021年
- 美國副廠藥品市場在2009年的收益達到356億美元
- 美國副廠藥品市場預測：2010∼2021年
- 美國副廠藥品市場分析
- 美國副廠藥品市場之主要企業
- Teva
- Mylan
- Sandoz
- Hospira
- Watson
- Biosimilars
第7章 美國OTC藥品市場：2011∼2021年
- 美國OTC藥品市場在2009年的收益達到194億美元
- 美國OTC市場預測
- 美國OTC市場分析
- 美國OTC市場之主要企業
- Johnson & Johnson
- Procter & Gamble
- Bayer
- Novartis
- Perrigo Company
第8章 專家見解
第9章 SWOT分析
圖表
Abstract
Do you want to know the effects of the Obama government' s legislation for US
healthcare? Insurance coverage will be extended, expanding the pharma market.
But at what price to the pharmaceutical industry in rebates and other costs?
Will the healthcare reforms underwrite another decade of growth in the US
pharma market, or has it reached its limits?
US Pharmaceutical Market Outlook 2011-2021 answers those questions with a
deep, wide-ranging survey of the market. Our report analyses the leading
therapeutic categories in the US market. We assess which areas have the
strongest potential for growth and the most-promising R&D pipelines. You will
also find out which areas are most threatened with contraction as patent
expiries occur. Order today, staying ahead.
We provide forecasts and discussions for the top drugs in the US market. We
profile the US market' s leading players, with analyses of their growth
strategies. Our report covers their plans to expand and diversify their
portfolios, restructure their operations and consolidate positions in emerging
markets. We provide revenue forecasts for the top companies in the US market
and worldwide, putting the US market in context.
Our new report also provides analyses of the US generic drug market and the US
OTC pharma market, studying the market drivers and restraints. We provide
forecasts for those markets, and for leading companies in those rising sectors.
This report contains interviews with experts on prospects for the US market
this decade, discussing matters such as:
- FDA funding and regulatory transparency
- The biosimilars market in light of the 2010 healthcare reforms
- The erosion of industry leadership to Europe
- The pressure on pricing within the US health insurance industry
- The legal and political complexities of the US pharma market this decade.
Analysis and expert opinion to aid your work - so you won' t be left behind
US Pharmaceutical Market Outlook 2011-2021 critically examines the world' s
most important pharma market. You will find sales forecasts, market share
analyses, discussions of products and analyses of commercial drivers and
restraints.
We include 120 tables and figures and two expert interviews (shown in the
accompanying lists). You can stay ahead by ordering our report today,
benefiting your analyses and commercial ideas.
US Pharmaceutical Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
- You will receive a detailed analysis of prospects for the US market' s
growth from 2011 to 2021, including forecasts for main therapeutic categories,
and those for the generic and OTC sectors
- You will find out how companies are performing in the US market, with
forecasts and discussions for the leading companies overall, and for leading
generics and OTC companies
- You will learn prospects for the leading products in the US pharma market,
with US revenue forecasts for top brands
- You will discover the legal, regulatory and economic drivers and
restraints operating in the US pharma market, especially implications of the
2010 healthcare reforms
- You will identify the key industry trends in this market, seeing
opportunities and market requirements
- You will read expert opinion from our survey, including full interview
transcripts.
How will the US pharma market develop, and which companies and products will
be best placed to benefit from legal, regulatory and economic changes? This
report gives you the trends and answers you need.
You can have our report today
Nobody with an interest in the US pharma market should overlook our new study.
We conclude that the US healthcare reforms will have important effects on the
pharma industry. Do you want to understand future trends and harness the
opportunities? Order our report now, making sure you don' t miss out. Please
let us help today.
Table of Contents
1. Executive Summary
- 1.1 US Pharmaceutical Market Summary
- 1.2 Contents Overview
- 1.3 Methods of Analysis
2. The US Pharma Market in 2010
- 2.1 The 2010 Healthcare Reforms
- 2.1.1 Existing Healthcare Coverage
- 2.1.1.1 Medicare
- 2.1.1.2 Medicaid
- 2.1.1.3 Other Public Programmes
- 2.1.1.4 Employer Funded Healthcare
- 2.1.1.5 Private Healthcare Insurance
- 2.1.2 The Cost of US Healthcare
- 2.1.3 The Provisions of the 2010 Healthcare Reforms
- 2.1.4 Opposition to Reforms
- 2.1.5 Benefits and Costs to the Pharmaceutical Industry of the 2010
Health Care Reforms
- 2.2 Other Influences on the US Market in 2010
- 2.2.1 Pricing Policy
- 2.2.2 The End of the Blockbuster Model?
- 2.2.3 The Regulatory Environment
- 2.2.3.1 FDA Stringency
- 2.2.3.2 Lack of Transparency
- 2.2.3.3 Overstretch
3. Overview of US Market, 2011-2021
- 3.1 US Market Revenues Can Rise Significantly
- 3.2 CNS Products Are The Largest Market Sector in 2010
- 3.2.1 Forecast for CNS Products
- 3.3 Cardiovascular Products
- 3.3.1 Forecast for Cardiovascular Products
- 3.3 Oncology Products
- 3.3.1 Forecast for Oncology Products
- 3.4 Anti-infective Products
- 3.4.1 Forecast for Anti-infective Products
- 3.5 Alimentary/Metabolism Products
- 3.5.1 Forecast for Metabolism Products
- 3.6 Other Products
4. Top Products in the US Market
- 4.1 Lipitor (Pfizer)
- 4.2 Plavix (Bristol-Myers Squibb)
- 4.3 Seretide (GlaxoSmithKline)
- 4.4 Seroquel (AstraZeneca)
- 4.5 Remicade (Johnson & Johnson)
5. Top Companies in the US Market
- 5.1 Pfizer
- 5.1.1 Pfizer' s Growth Strategy
- 5.1.1.1 New Markets
- 5.1.1.2 Portfolio Management
- 5.1.1.3 Diversification and Restructuring
- 5.1.2 Forecast for Pfizer
- 5.2 Roche
- 5.2.1 Roche' s Growth Strategy
- 5.2.1.1 New Markets
- 5.2.1.2 Portfolio Management
- 5.2.1.3 Diversification and Restructuring
- 5.2.2 Forecast for Roche
- 5.3 AstraZeneca
- 5.3.1 AstraZeneca' s Growth Strategy
- 5.3.1.1 New Markets
- 5.3.1.2 Portfolio Management
- 5.3.1.3 Diversification and Restructuring
- 5.3.2 Forecast for AstraZeneca
- 5.4 Merck & Co.
- 5.4.1 Merck & Co' s Growth Strategy
- 5.4.1.1 New Markets
- 5.4.1.2 Portfolio Management
- 5.4.1.3 Diversification and Restructuring
- 5.4.2 Forecast for Merck & Co.
- 5.5 Novartis
- 5.5.1 Novartis' Growth Strategy
- 5.5.1.1 New Markets
- 5.5.1.2 Portfolio Management
- 5.5.1.3 Diversification and Restructuring
- 5.5.2 Forecast for Novartis
6. US Generics Market 2011-2021
- 6.1 The US Generics Market Achieved 2009 Revenues of $35.6bn
- 6.2 Forecast for the US Generics Market, 2010-2021
- 6.2.1 US and China: Generics
- 6.3 Analysis of the US Generics Market
- 6.3.1 Pro-Generic Government Policies
- 6.3.2 Many More Blockbuster Products Will Become Susceptible to Generic
Competition
- 6.3.3 Pricing Pressure and Regulation
- 6.3.4 The ANDA Backlog
- 6.4 Key Players in the US Generics Market
- 6.4.1Teva
- 6.4.2 Mylan
- 6.4.3 Sandoz
- 6.4.4 Hospira
- 6.4.5 Watson
- 6.5 Biosimilars
7. US OTC Market 2011-2021
- 7.1 The US OTC Market Achieved 2009 Revenues of $19.4bn
- 7.2 Forecast for the US OTC Market
- 7.3 Analysis of the US OTC Market
- 7.3.1 OTC Products Have Several Advantages
- 7.3.2 Rx-to-OTC Switching: The OTC Product Pipeline
- 7.3.3 Difficulties with OTC Switching
- 7.3.4 Sales Channels
- 7.4 Leading Companies in the US OTC Market
- 7.4.1 Johnson & Johnson
- 7.4.2 Procter & Gamble
- 7.4.3 Bayer
- 7.4.4 Novartis
- 7.4.5 Perrigo Company
8. Expert Opinions
- 8.1 Interview with Robert J. Easton
- 8.1.1 Pros and Cons of the 2010 Health Care Reform Bills
- 8.1.2 The Reform of Pricing
- 8.1.3 Different Strategies in the Industry
- 8.1.4 On Emerging Markets and the Loss of American Industry Leadership
- 8.2 Interview with Steven A. Grossman
- 8.2.1 On The Prospects for Health Care Reform
- 8.2.2 Opposition to the Reforms
- 8.2.3 Effects of the Bill
- 8.2.4 On Biosimilars Prospects
- 8.2.5 On FDA Regulation
- 8.2.6 On the Legal Challenge to the Industry
- 8.2.7 On FDA Funding
9. SWOT Analysis of US Market: Conclusions
- 9.1 Strengths of the US Market
- 9.1.1 The US Pharma Market is the Largest in the World
- 9.1.2 The 2010 Health Care Reforms Will Increase Coverage
- 9.1.3 Unmet Market Needs
- 9.2 Weaknesses of the US Market
- 9.2.1 The US Market Has Low Growth Rates
- 9.2.2 Margins Can Only Get Smaller
- 9.2.3 US Leadership and Centrality Have Decreased
- 9.3 Opportunities in the US Market
- 9.3.1 Biologicals and Biosimilars Will Grow
- 9.3.2 Good Prospects in Oncology
- 9.3.3 Opportunities in Generics and OTC Markets
- 9.4 Threats to the US Market
- 9.4.1 Opposition to Reforms
- 9.4.2 FDA Shortcomings
- 9.4.3 The Competitive Threat of China
- 9.5 Conclusions
List of Tables
- Table 2.1. Global Pharmaceutical Market by Region, Revenues ($bn), Share
of Global Market (%), 2009
- Table 2.2. Top 10 Global Pharmaceutical Markets, Revenues ($bn), Share of
Global Market (%), 2009
- Table 2.3. Types of Employer-Funded Healthcare Provision, 2010
- Table 2.4. US Government Healthcare Expenditure ($bn), 2007
- Table 2.5. Provisions of the 2010 Healthcare Reforms
- Table 2.6. Key Benefits and Costs to the Pharmaceutical Industry of the
2010 Health Care Reforms
- Table 3.1. US Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 3.2. US Pharma Market and China Pharma Market, Revenues ($bn),
Annual Growth (%), CAGR (%), 2009-2021
- Table 3.3. Sectors in the US Market, Total Revenues ($bn), Annual Growth
Rate (%), Share of Market (%), 2009
- Table 3.4. Top Ten Products in the CNS Sector, US Revenues ($bn), 2009
- Table 3.5. CNS Sector, Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 3.6. Top Ten Products in the Cardiovascular Sector, US Revenues
($bn), 2009
- Table 3.7. Cardiovascular Sector, Revenues ($bn), Annual Growth (%), CAGR
(%), 2009-2021
- Table 3.8. Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009
- Table 3.9. Oncology Sector, Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 3.10. Top Ten Products in the Anti-infectives Sector, US Revenues
($bn), Market Share (%), 2009
- Table 3.11. Anti-infectives Sector, Revenues ($bn), Annual Growth (%),
CAGR (%), 2009-2021
- Table 3.12. Top Ten Products in the Alimentary/Metabolic Sector, US
Revenues ($bn), Market Share (%), 2009
- Table 3.13. Alimentary/Metabolic Sector, Revenues ($bn), Annual Growth
(%), CAGR (%), 2009-2021
- Table 3.14. Other Sectors, Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 4.1. Top 10 Products in the US Market, US Revenues ($bn), 2009
- Table 4.2. Lipitor US Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 4.3. Plavix US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
- Table 4.4. Seretide US Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 4.5. Seroquel US Revenues ($bn), US Revenues ($bn), Annual Growth
(%), CAGR (%), 2009-2021
- Table 4.6. Remicade US Revenues ($bn), US Revenues ($bn), Annual Growth
(%), CAGR (%), 2009-2021
- Table 5.1. Top Companies in the US Market, US Revenues ($bn), Total
Revenues, Market Share (%), 2009
- Table 5.2. Pfizer Products Approaching Patent Expiry, 2010
- Table 5.3. Pfizer Pipeline, Phase III and Later, 2010
- Table 5.4. Pfizer US Revenues ($bn), Global Revenues ($bn), Annual Growth
(%), CAGR (%), Share of US Market (%), 2009-2021
- Table 5.5. Roche Products Approaching Patent Expiry, 2010
- Table 5.6. Roche Pipeline, Phase III and Later, 2010
- Table 5.7. Roche US Revenues ($bn), Global Revenues ($bn), Annual Growth
(%), CAGR (%), Share of US Market (%), 2009-2021
- Table 5.8. AstraZeneca Products Approaching Patent Expiry, 2010
- Table 5.9. AstraZeneca Pipeline, Phase III and Later, 2010
- Table 5.10. AstraZeneca US Revenues ($bn), Global Revenues ($bn), Annual
Growth (%), CAGR (%), Share of US Market (%), 2009-2021
- Table 5.11. Merck & Co Products Approaching Patent Expiry, 2010
- Table 5.12. Merck & Co Pipeline, Phase III and Later, 2010
- Table 5.13. Merck & Co US Revenues ($bn), Global Revenues ($bn), Annual
Growth (%), CAGR (%), Share of US Market (%), 2009-2021
- Table 5.14. Novartis Products Approaching Patent Expiry, 2010
- Table 5.15. Novartis Pipeline, Phase III and Later, 2010
- Table 5.16. Novartis US Revenues ($bn), Global Revenues ($bn), Annual
Growth (%), CAGR (%), Share of US Market (%), 2009-2021
- Table 6.1. Top National Generics Markets, Revenues ($bn), Share of Global
Market (%), 2009
- Table 6.2. US Generic Revenues ($bn), Annual Growth (%), CAGR (%), Share
of US Market (%), 2009-2021
- Table 6.3. US and China Generic Revenues ($bn), Annual Growth (%), CAGR
(%), 2009-2021
- Table 6.4. Top Companies in the US Generics Market, 2009, Revenues ($bn),
Market Share (%), 2009
- Table 6.5. Teva US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
- Table 6.6. Mylan US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
- Table 6.7. Sandoz US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
- Table 6.8. Hospira US Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 6.9. Watson US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
- Table 6.10. Some Companies in the Biosimilars Market, 2010
- Table 7.1. OTC Markets Worldwide, Revenues ($bn), Global Market Share (%),
2009
- Table 7.2. US OTC Market, Revenues ($bn), Annual Growth (%), CAGR (%),
2009-2021
- Table 7.3. US and China OTC Markets, Revenues ($bn), Annual Growth (%),
CAGR (%), 2009-2021
- Table 7.4. Top Companies in the US OTC Market, Revenues ($bn), Market
Share (%), 2009
- Table 7.5. Johnson & Johnson OTC Revenues ($bn), Market Share (%), CAGR
(%), 2009-2021
- Table 7.6. Procter & Gamble OTC Revenues ($bn), Market Share (%), CAGR
(%), 2009-2021
- Table 7.7. Bayer OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
- Table 7.8. Novartis OTC Revenues ($bn), Market Share (%), CAGR (%),
2009-2021
- Table 7.9. Perrigo Company OTC Revenues ($bn), Market Share (%), CAGR (%),
2009-2021
List of Figures
- Figure 2.1. Global Pharmaceutical Market by Region, Revenues ($bn), 2009
- Figure 2.2. Top 10 National Pharmaceutical Markets, Revenues ($bn), 2009
- Figure 2.3. US Government Health Care Expenditure ($bn), 2007
- Figure 3.1. US Pharma Market, Revenues ($bn), 2009-2021
- Figure 3.2. US and Chinese Pharma Markets, Revenues ($bn), 2009-2021
- Figure 3.3. Sectors in the US Market, Total Revenues ($bn), 2009
- Figure 3.4. Top Ten Products in the CNS Sector, US Revenues ($bn), 2009
- Figure 3.5. CNS Sector, US Revenues ($bn), 2009-2021
- Figure 3.6. Top Ten Products in the Cardiovascular Sector, US Revenues
($bn), 2009
- Figure 3.7. Cardiovascular Sector, US Revenues ($bn), 2009-2021
- Figure 3.8. Top Ten Products in the Oncology Sector, US Revenues ($bn),
2009
- Figure 3.9. Oncology Sector, US Revenues ($bn), 2009-2021
- Figure 3.10. Top Ten Products in the Anti-infectives Sector, US Revenues
($bn), Market Share (%), 2009
- Figure 3.11. Anti-infectives Sector, US Revenues ($bn), 2009-2021
- Figure 3.12. Top Ten Products in the Alimentary/Metabolic Sector, 2009
- Figure 3.13. Alimentary/Metabolic Sector, Revenues ($bn), 2009-2021
- Figure 4.1. Top Ten Products in the US Market, Revenues ($bn), 2009
- Figure 4.2. Lipitor US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 4.3. Lipitor US Revenues ($bn), 2009-2021
- Figure 4.4. Plavix US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 4.5. Plavix US Revenues ($bn), 2009-2021
- Figure 4.6. Seretide US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 4.7. Seretide US Revenues ($bn), 2009-2021
- Figure 4.8. Seroquel US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 4.9. Seroquel US Revenues ($bn), 2009-2021
- Figure 4.10. Remicade US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 4.11. Remicade US Revenues ($bn), 2009-2021
- Figure 5.1. Top Ten Companies in the US Market, Revenues ($bn), 2009
- Figure 5.2. Pfizer US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 5.3. Pfizer US Revenues ($bn), Global Revenues ($bn), 2009-2021
- Figure 5.4. Roche US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 5.5. Roche US Revenues ($bn), Global Revenues ($bn), 2009-2021
- Figure 5.6. AstraZeneca US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 5.7. AstraZeneca US Revenues ($bn), Global Revenues ($bn), 2009-2021
- Figure 5.8. Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 5.9. Merck & Co US Revenues ($bn), Global Revenues ($bn), 2009-2021
- Figure 5.10. Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009
- Figure 5.11. Novartis US Revenues ($bn), Global Revenues ($bn), 2009-2021
- Figure 6.1. US Generic Sales and Branded Product Sales ($bn), Share of
Overall Market Revenues (%), 2009
- Figure 6.2. US Generic and Branded Products Share of Overall Market Volume
(%), 2009
- Figure 6.3. US Generic and Branded Products Share of Overall Market Volume
(%), 2009
- Figure 6.4. US Generic Market Revenues ($bn), 2009-2021
- Figure 6.5. US and China Generic Market Revenues ($bn), 2009-2021
- Figure 6.6. Top Companies in the US Generics Market, 2009, Revenues ($bn),
2009
- Figure 6.7. Teva US Revenues ($bn), 2009-2021
- Figure 6.8. Mylan US Revenues ($bn), 2009-2021
- Figure 6.9. Sandoz US Revenues ($bn), 2009-2021
- Figure 6.10. Hospira US Revenues ($bn), 2009-2021
- Figure 6.11. Watson US Revenues ($bn), 2009-2021
- Figure 7.1. US OTC and Rx Revenues ($bn), 2009
- Figure 7.2. OTC Markets Worldwide, Revenues ($bn), 2009
- Figure 7.3. US OTC Market, Revenues ($bn), 2009-2021
- Figure 7.4. US and China OTC Markets, Revenues ($bn), 2009-2021
- Figure 7.5. Top Companies in the US OTC Market, Revenues ($bn), 2009
- Figure 7.6. Johnson & Johnson OTC Revenues ($bn), 2009-2021
- Figure 7.7. Procter & Gamble OTC Revenues ($bn), 2009-2021
- Figure 7.8. Bayer OTC Revenues ($bn), 2009-2021
- Figure 7.9. Novartis OTC Revenues ($bn), 2009-2021
- Figure 7.10. Perrigo Company OTC Revenues ($bn), 2009-2021
|
